Efficacy Study of Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
Aneurysmal Subarachnoid Hemorrhage
Enrolment: 120 · Results not recorded
Loading the evidence…
Nutraceutical
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Aneurysmal Subarachnoid Hemorrhage
Enrolment: 120 · Results not recorded
Cancer-related Fatigue
Enrolment: 323 · Results not recorded
Cancer-related Fatigue
Enrolment: 17 · Results not recorded
Cancer-related Fatigue · Neutropenia, Malignant
Enrolment: 67 · Results not recorded
Acute Stroke
Enrolment: 86 · Results not recorded
Cancer-related Fatigue · Survival · Tumor, Esophageal
Enrolment: 48 · Results not recorded
Cancer-related Fatigue
Enrolment: 6 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Doxorubicin-induced cardiotoxicity and heart failure with a single intraperitoneal injection of doxorubicin 20 mg/kg and euthanasia 5 days later; in vitro doxorubicin 0.5 microM for 24 hours
Astragalus polysaccharide pre-treatment restored autophagic flux, improved ejection fraction and fractional shortening and reduced doxorubicin-induced apoptosis (TUNEL 22.28% with doxorubicin versus 11.53% with doxorubicin plus extract), with the benefit reversed by rapamycin.
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.